Chart Events
Performance Outlook
| Previous Close | 11.39 |
| Open | 11.54 |
| Bid | 11.53 x 1100 |
| Ask | 11.86 x 1100 |
| Day's Range | 11.51 - 11.72 |
| 52 Week Range | 9.07 - 17.05 |
| Volume | |
| Avg. Volume | 7,042 |
| Market Cap | 802.194M |
| Beta (5Y Monthly) | 0.94 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for VALN
Related Research
- Valneva SEDaily – Vickers Top Buyers & Sellers for 06/05/2023The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.RatingFair ValueEconomic Moat6 months agoArgus Research
- Insider Monkey
Valneva SE (NASDAQ:VALN) Q3 2023 Earnings Call Transcript
Valneva SE (NASDAQ:VALN) Q3 2023 Earnings Call Transcript November 9, 2023 Operator: Good day and thank you for standing by. Welcome to the Valneva 9 Months 2023 Financial Results Call. [Operator Instructions]. I would now like to hand the conference over to your speaker today, Joshua Drumm, VP, Investor Relations. Please go ahead. Joshua Drumm: […]
- BioPharma Dive
Valneva’s chikungunya vaccine approved by FDA
The preventive shot is the first to receive regulatory approval for the mosquito-borne illness, which is growing in prevalence worldwide.
- Reuters
FDA finds no misconduct at trial sites for Pfizer's Lyme disease shot- Care Access
The U.S. health regulator did not find any misconduct at clinical sites managed by Care Access for Pfizer and French partner Valneva's trial of a Lyme disease vaccine candidate, the contract research firm said on Wednesday. Pfizer and Valneva said in February they will stop testing the vaccine in roughly half of U.S. patients in a late-stage study, due to a breach of clinical trial guidelines by a third-party contractor. The vaccine for Lyme disease, which causes infections that are transmitted to humans through ticks, has shown a "strong immune response" in a mid-stage study in both children and adolescents a month after a booster dose.
